30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Employees and job applicants in New Jersey who are lawful medical cannabis users can hold their head...
Read More >
Generally, indemnity agreements in construction contracts are a promise by which one party (the inde...
Read More >
In this one-hour webcast, Wendy will help your understanding of how to best manage Independent Contr...
Read More >
On May 9th, Councilman Bill Henry introduced CCB #19-389, which proposes to modify the number of ren...
Read More >
The DE OFCCP Week in Review (WIR) is a simple, fast and direct summary of relevant happenings in the...
Read More >
The national conversation around issues of gender equality and the demands for pay equity is driving...
Read More >